The content on this site is intended for healthcare professionals only
Prof Yi-Long Wu speaks to ecancer about early-phase results evaluating SHR-A2009, a novel HER3-directed antibody-drug conjugate, in combination with a third-generation EGFR tyrosine kinase inhibitor in patients with EGFR-mutant non-small cell lung cancer.
The combination demonstrated encouraging clinical activity in both previously treated and first-line settings, with particularly strong progression-free survival signals in treatment-naïve patients.
Safety was manageable overall, although some higher-grade adverse events, including interstitial lung disease, were observed and require careful monitoring.
These findings support further development of this combination, with a phase III trial already underway to confirm its potential as a new first-line treatment option in EGFR-mutant lung cancer.
T-cell engagers in lung cancer: Strategies to prevent and manage toxicities
ATR inhibitor plus durvalumab does not improve survival over docetaxel in advanced NSCLC
Gotistobart improves survival and response over docetaxel in previously treated squamous lung cancer
Immunoprevention and early detection of lung cancer in Africa: The LUNG-GUARD Platform
Tarlatamab improves survival over chemo in 2L SCLC regardless of prior immunotherapy or chemo
Zongertinib shows high response rates in first-line HER2-mutant advanced NSCLC
Osimertinib plus chemo improves survival across high-risk subgroups in EGFR-mutated aNSCLC
Perioperative durvalumab in addition to neoadjuvant chemotherapy shows positive results in patients with stage IIIa(N2) NSCLC
